201 related articles for article (PubMed ID: 19225233)
1. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment--proof of concept.
Rolstad S; Nordlund A; Eckerström C; Gustavsson MH; Zetterberg H; Wallin A
Dement Geriatr Cogn Disord; 2009; 27(2):194-200. PubMed ID: 19225233
[TBL] [Abstract][Full Text] [Related]
2. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report.
Rolstad S; Nordlund A; Eckerström C; Gustavsson MH; Zetterberg H; Wallin A
Dement Geriatr Cogn Disord; 2009; 28(2):110-5. PubMed ID: 19684400
[TBL] [Abstract][Full Text] [Related]
3. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment.
Rozzini L; Chilovi BV; Bertoletti E; Conti M; Del Rio I; Trabucchi M; Padovani A
Int J Geriatr Psychiatry; 2006 Jun; 21(6):550-5. PubMed ID: 16642542
[TBL] [Abstract][Full Text] [Related]
5. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment.
Eckerström C; Andreasson U; Olsson E; Rolstad S; Blennow K; Zetterberg H; Malmgren H; Edman A; Wallin A
Dement Geriatr Cogn Disord; 2010; 29(4):294-300. PubMed ID: 20389071
[TBL] [Abstract][Full Text] [Related]
6. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
Herukka SK; Hallikainen M; Soininen H; Pirttilä T
Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371
[TBL] [Abstract][Full Text] [Related]
7. High education may offer protection against tauopathy in patients with mild cognitive impairment.
Rolstad S; Nordlund A; Eckerström C; Gustavsson MH; Blennow K; Olesen PJ; Zetterberg H; Wallin A
J Alzheimers Dis; 2010; 21(1):221-8. PubMed ID: 20413900
[TBL] [Abstract][Full Text] [Related]
8. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
Andersson C; Blennow K; Almkvist O; Andreasen N; Engfeldt P; Johansson SE; Lindau M; Eriksdotter-Jönhagen M
Neurobiol Aging; 2008 Oct; 29(10):1466-73. PubMed ID: 17512092
[TBL] [Abstract][Full Text] [Related]
9. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
[TBL] [Abstract][Full Text] [Related]
10. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
12. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
[TBL] [Abstract][Full Text] [Related]
14. False recognition correlates with amyloid-beta (1-42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment.
Hildebrandt H; Haldenwanger A; Eling P
J Alzheimers Dis; 2009; 16(1):157-65. PubMed ID: 19158431
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal metabolic and cognitive changes in mild cognitive impairment patients.
Olson BL; Holshouser BA; Britt W; Mueller C; Baqai W; Patra S; Petersen F; Kirsch WM
Alzheimer Dis Assoc Disord; 2008; 22(3):269-77. PubMed ID: 18580584
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.
Stomrud E; Hansson O; Blennow K; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2007; 24(2):118-24. PubMed ID: 17622715
[TBL] [Abstract][Full Text] [Related]
17. Cognitive profiles of incipient dementia in the Goteborg MCI study.
Nordlund A; Rolstad S; Göthlin M; Edman A; Hansen S; Wallin A
Dement Geriatr Cogn Disord; 2010; 30(5):403-10. PubMed ID: 20975271
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients.
Vicini Chilovi B; Conti M; Zanetti M; Mazzù I; Rozzini L; Padovani A
Dement Geriatr Cogn Disord; 2009; 27(4):390-8. PubMed ID: 19339777
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
